Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042424 | 0.90 | CYP2C9 (0.58) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL8126154 | 0.88 | CYP2C9 (0.70) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL20042418 | 0.88 | MMP2 (0.62) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL20042417 | 0.87 | PTGS2 (0.67) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL18180817 | 0.85 | CYP2C9 (0.80) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL20042416 | 0.83 | CYP2C9 (0.78) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL8114069 | 0.82 | PTGS2 (0.79) | CYP2C9PTGS2PTGS1MMP2PDPK1 | |
| SCHEMBL20042427 | 0.82 | PTGS2 (0.79) | CYP2C9PTGS2PTGS1MMP2CA1 | |
| SCHEMBL6906481 | 0.82 | PTGS2 (0.79) | CYP2C9PTGS2PTGS1MMP2PDPK1 | |
| SCHEMBL20044911 | 0.82 | PTGS2 (0.80) | CYP2C9PTGS2PTGS1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | ABCG2, FABP1, FABP2 | CYP2C9 67/4885PTGS2 3366/4885PTGS1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.